Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YPEG-rhGH dose-finding in children with short stature (ISS, SGA, TS)
NCT05838885Phase 2Completed
- Sponsor
- Xiamen Tebao Biological Engineering Co., Ltd.
- Start
- Feb 2022
- Primary completion
- Oct 2023
- Modality
- PEGylated Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of genotropin miniquick in Idiopathic Short Stature (ISS), Small for gestational age (SGA) and Turner syndrome (TS) (4 arms), sponsored by Xiamen Tebao Biological Engineering Co., Ltd. Primary endpoints: Pharmacokinetic-area under plasma concentration versus time curve at 52 weeks, Pharmacokinetic-maximum serum concentration at 52 weeks and 5 more. Started Feb 2022; status: completed.
02
Drugs
genotropin miniquick
03
Conditions
Idiopathic Short Stature (ISS)Small for gestational age (SGA)Turner syndrome (TS)
Beyond the preview
Go deeper on NCT05838885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05838885.